Chinese inhibitor drug candidate becomes first to enter phase
Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312.
SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally.
The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations.
The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy.
Related articles
Brazil replaces injured goalkeeper Ederson in Copa America squad
RIO DE JANEIRO (AP) — Brazil coach Dorival Júnior has replaced injured goalkeeper Ederson with Sao P2024-05-21China to launch national survey on cultural relics
(Xinhua) 10:59, October 28, 2023BEIJING, Oct. 27 (Xinhua) -- China will launch its fourth survey on2024-05-21Defending champion Nuggets finish second in West, beating Grizzlies 126
MEMPHIS, Tenn. (AP) — Jamal Murray scored 21 points, Nikola Jokic had 15 points and 15 rebounds, and2024-05-21Ningxia delicacies tempt int'l diners' palates
(Xinhua) 11:03, October 28, 2023YINCHUAN, Oct. 28 (Xinhua) -- Red wine produced from the Helan Mount2024-05-21What's next for Iran after death of its president in crash?
JERUSALEM (AP) — The death of Iran’s president is unlikely to lead to any immediate changes in Iran’2024-05-21Tokyo International Film Festival kicks off as China's Zhang Yimou wins lifetime award
(Xinhua) 13:23, October 25, 2023TOKYO, Oct. 24 (Xinhua) -- The 36th Tokyo International Film Festiva2024-05-21
atest comment